Skip to main content
Home > BC Innovations > Targets & Mechanisms

Chronological Index of : Targets & Mechanisms

 Current Issue
  • Structural SERT-ainty

    SERT crystallography defines two SSRI binding sites

    The crystal structure of the serotonin transporter has revealed a primary ligand-binding site and an allosteric site that offer opportunities for new drug design.

    Published on 4/21/2016
  • Figure: An SSRI in-SERTs twice

    Structural SERT-ainty Targets & Mechanisms An SSRI in-SERTs twice In a study published in Nature, a team from the Vollum Institute at Oregon Health & Science University (OHSU) has finally solved the crystal …

    Published on 4/21/2016
  • Box: Questioning UCP1

    Brown fat heats up Targets & Mechanisms Questioning UCP1 While there is evidence that manipulating targets such as FGF21, USF1 and SLIT2 promote both metabolic benefits and brown fat activity, it is still not clear…

    Published on 3/10/2016
  • Figure: Feel the burn

    Brown fat heats up Targets & Mechanisms Feel the burn Three studies have identified new molecular targets to treat obesity and metabolic diseases by enhancing thermogenesis - a process in which brown or beige …

    Published on 3/10/2016
  • Table: BioCentury Product Profile

    Brown fat heats up Targets & Mechanisms BioCentury Product Profile BioCentury Product Profile INNOVATION STAGE Product A small molecule inhibitor of the protease FAP C-terminal fragment of SLIT2 Concept A …

    Published on 3/10/2016
  • Table: Brown and beige fat targets

    Brown fat heats up Targets & Mechanisms Brown and beige fat targets Selected targets for modifying beige or brown fat to treat obesity and metabolic diseases, identified in the Distillery section of BioCentury …

    Published on 3/10/2016
  • Table: Brown and beige fat targets

    Brown fat heats up Targets & Mechanisms Brown and beige fat targets Selected targets for modifying beige or brown fat to treat obesity and metabolic diseases, identified in the Distillery section of BioCentury …

    Published on 3/10/2016
  • Brown fat heats up

    Casting a wide net for brown and beige fat targets in metabolic diseases

    The list of obesity targets in brown and beige fat is extending well beyond FGF21, with three studies showing new possibilities since the start of the year.

    Published on 3/10/2016
  • Targeting TMP

    New ways to target bacterial DNA synthesis

    Mechanistic insights into the unique chemistry of a bacteria-specific thymidylate synthesis pathway could lead to better antibiotics.

    Published on 3/3/2016
  • Figure: AKTing on SHANK3

    Rescue mission Targets & Mechanisms AKTing on SHANK3 A team at Novartis Institutes for BioMedical Research (NIBR) has identified three new autism targets (purple) and is designing small molecules against the …

    Published on 3/3/2016
  • Table: BioCentury Product Profile

    Rescue mission BioCentury Product Profile INNOVATION STAGE Product A small molecule inhibitor of CLK-2 or PPP2CA, or activator of AKT, that crosses the blood-brain barrier Concept A treatment for autism that …

    Published on 3/3/2016
  • Rescue mission

    Rescuing synapses in SHANK3 mice

    Two studies on the autism target SHANK3 suggest some symptoms can be reversed even after childhood and present a new small molecule strategy.

    Published on 3/3/2016
  • Borrowing for Zika

    Additional strategies to combat Zika spread

    While companies and agencies chase traditional routes to a Zika vaccine, some groups are borrowing strategies from Ebola, dengue and malaria for alternative ways to stop the disease.

    Published on 2/25/2016
  • Table: Finding funds for Zika

    Borrowing for Zika Targets & Mechanisms Finding funds for Zika Since January 2016, at least seven public funding institutions or foundations have announced grants or called for initiatives for research into the …

    Published on 2/25/2016
  • Figure: One fox two fox

    Staking out foxholes: Figure: One fox two fox Staking out foxholes Targets & Mechanisms One fox, two fox Researchers from Memorial Sloan Kettering Cancer Center have shown the transcription factor FOXO1 keeps Tregs …

    Published on 2/18/2016
  • Figure: Surveillance state

    Staking out foxholes: Figure: Surveillance state Staking out foxholes Targets & Mechanisms Surveillance state Researchers from Memorial Sloan Kettering Cancer Center have identified a population of immune cells that…

    Published on 2/18/2016
  • Staking out foxholes

    Two MSKCC studies, two potential ways to improve antitumor immunity

    A pair of MSKCC studies unravels new biology for dialing down immune suppression and dialing up immunosurveillance.

    Published on 2/18/2016
  • Complementary ideas

    C4 levels drive schizophrenia risk

    A link between complement and schizophrenia raises new possibilities for treatment and a debate about pruning.

    Published on 2/11/2016
  • Figure: Structured risk

    Complementary ideas Targets & Mechanisms Structured risk A Harvard group has traced one of the strongest genetic risk factors for schizophrenia to the C4 gene. The team showed structural variation in C4 controls …

    Published on 2/11/2016
  • LRRK2 back on track

    MJFF's LRRK2 Safety Initiative brings competitors together to speed drugs toward the clinic

    An MJFF-pharma initiative has calmed concerns over the lung toxicity of preclinical LRRK2 inhibitors, but left open questions about the basic biology of the target.

    Published on 1/21/2016
  • Box: Getting to the stem of DMD

    Snipping vs. skipping for DMD Targets & Mechanisms Getting to the stem of DMD Skeletal muscle stem cells - also known as satellite cells - have been largely overlooked in treatment of Duchenne muscular dystrophy (…

    Published on 1/21/2016
  • Figure: Exon skipping vs. CRISPR

    Snipping vs. skipping for DMD Targets & Mechanisms Exon skipping vs. CRISPR With the efficacy of antisense and small molecule therapeutics that bypass disease-causing mutations in Duchenne muscular dystrophy (DMD) …

    Published on 1/21/2016
  • Snipping vs. skipping for DMD

    Why CRISPR might be better than exon skipping for DMD

    Three studies show gene editing in DMD can improve muscle function in mice, but this week's setbacks for the late-stage exon-skipping compounds may have raised the bar for efficiency.

    Published on 1/21/2016
  • Moot point in AD

    A master regulator means there's no need to pick a side in β-amyloid vs. tau

    A new target upstream of β-amyloid and tau could get around the need to pick one pathway over the other.

    Published on 1/14/2016
  • Figure: One inhibitor, two pathways

    Moot point in AD Targets & Mechanisms One inhibitor, two pathways Two studies from an Emory University team showed AEP sits atop both the tau and β-amyloid pathways in Alzheimer's disease (AD) and suggest …

    Published on 1/14/2016

< Previous   1  2  3  4  5  Next >

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993